Medtronic plc
Medtronic CFO Resignation and Interim CFO Appointment Announced
Summary
On June 21, 2024, Karen L. Parkhill, Executive Vice President and Chief Financial Officer of Medtronic plc, notified the Company of her decision to resign, effective August 2, 2024. Gary Corona, currently Senior Vice President, Global Financial Planning and Analysis, has been appointed as interim CFO, effective upon Ms. Parkhill's departure. A press release announcing these changes is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Profitelligence Alerts
Get alerts for MDT
Be first to know when Medtronic plc files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Medtronic plc
Medtronic plc is a leading global healthcare technology company that designs, manufactures, and sells innovative medical devices and therapies used in various medical procedures. The primary function of Medtronic is to improve healthcare outcomes by providing advanced therapeutic solutions. Its extensive product portfolio includes cardiac and vascular devices, diabetes-related products, minimally invasive therapies, and neurosurgical technologies. Medtronic plays a vital role in the medical device industry, catering to cardiovascular treatment, advanced diabetes management, spinal and musculoskeletal therapy, and more. Notably, the company is renowned for its pacemaker technology and is a pivotal player in cardiac care. The company's innovations significantly impact the healthcare sector by enhancing the quality of life for patients worldwide and improving the effectiveness of medical treatments. As a key player in the medical device market, Medtronic is instrumental in setting industry standards and advancing medical technology through continuous research and development. Founded in 1949 and headquartered in Dublin, Ireland, Medtronic's global presence underscores its substantial contribution to the healthcare industry across various continents.
Official SEC Documents
Advertisement